MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cardiovascular, Cardiac, Cardiology, Cardiometabolic Companies _ Imaging, Diagnostics, Health IT & Medical Devices
Elucid Bioimaging Inc.
Organization & Developments: Elucid
Parents
Elucid Bioimaging Inc.
Children
*Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to measure coronary blockages non-invasively and the extent of ischemia
*Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection.
*Its AI-powered imaging analysis software is designed to understand the root cause of cardiovascular disease deeply.
*PlaqueIQ powers Elucid's plaque analysis software, the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against tens of thousands of tissue annotations
2023: Elucid scores $80M for AI imaging analysis software and more digital health fundings
2024: Elucid wins FDA 510(k) nod for heart plaque image analysis software
Jumps
Finance & Acquisitionss: Elucid
Key People: Elucid